|
Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma. |
|
|
Honoraria - Bristol-Myers Squibb |
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma |
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Roche |
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst) |
|
|
Stock and Other Ownership Interests - Adaptive Biotechnologies; Ascentage Pharma; Beigene; Elucida Oncology; Imvaq Therapeutics; Kleo Pharmaceuticals; Linnaeus Therapeutics; Potenza Therapeutics; Serametrix; Tizona Therapeutics, Inc.; Trieza Therapeutics |
Honoraria - American Association for Cancer Research; Esanex; Institut Jules Bordet |
Consulting or Advisory Role - Adaptive Biotechnologies; Advaxis; Amgen; Apricity Therapeutics; Array BioPharma; Ascentage Pharma; Astellas Pharma; Bayer; Beigene; Bristol-Myers Squibb; Celgene; Chugai Pharma; F-Star Biotechnology; Genentech; Kleo Pharmaceuticals; Lilly; MedImmune; Merck; Neon Therapeutics; Ono Pharmaceutical; Polaris; Polynoma; Potenza Therapeutics; PsiOxus Therapeutics; PsiOxus Therapeutics; PureTech; Sellas Life Sciences; Serametrix; Surface Oncology; Syndax; Tizona Therapeutics, Inc.; Trieza Therapeutics |
Research Funding - Bristol-Myers Squibb (Inst); F-Star Therapeutics; Genentech/Roche (Inst); Incyte (Inst); Leap Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst) |
Patents, Royalties, Other Intellectual Property - ALPHAVIRUS REPLICON PARTICLES EXPRESSING TRP2; Engineered Vaccinia Viruses for Cancer Immunotherapy; I am a co-inventor and receive royalties for a blood test for monitoring myeloid derived suppressor cells.; I am a co-inventor on a patent for Anti-CD40 agonist mAb fused to Monophosphoryl Lipid A (MPL) for cancer therapy; I am a co-inventor on a patent for CAR+ T cells targeting differentiation antigens as means to treat cancer; I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.; I am co-inventor and receive royalties for a patent for immune modulating antibodies. |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Celgene; Chugai Pharma; Janssen; MedImmune; Novartis; Ono Pharmaceutical; Potenza Therapeutics; Roche; Tizona Therapeutics, Inc. |
|
|
Employment - Bristol-Myers Squibb (I); Bristol-Myers Squibb (I); Celgene (I); Kleo Pharmaceuticals (I) |
Consulting or Advisory Role - AstraZeneca; Merck; Moderna Therapeutics |
Research Funding - Bristol-Myers Squibb (Inst) |
Other Relationship - Clinical Care Options; Potomac Center for Medical Education |
|
|
Consulting or Advisory Role - Biodesix; Celldex; Corvus Pharmaceuticals; Genentech/Roche; Immunocore; Iovance Biotherapeutics; Merck; Nektar; Pfizer |
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Apexigen |
|
|
Honoraria - Bristol-Myers Squibb; Merck |
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; Merck; Newlink Genetics; Novartis |
Research Funding - Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst) |
|
|
Consulting or Advisory Role - Aduro Biotech; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; CStone Pharmaceuticals; EMD Serono; Gritstone Bio; Horizon Pharma; IFM Therapeutics; Imugene; Kyn therapeutics; Merck; Pfizer; Pieris Pharmaceuticals; PsiOxus Therapeutics; PureTech; Roche/Genentech; Synlogic; TRM Oncology |
Research Funding - Bristol-Myers Squibb; Incyte; MedImmune; Merck; Pfizer; Roche/Genentech |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; Celldex; Genmab; Takeda |
Consulting or Advisory Role - Aduro Biotech; Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen Oncology (Inst); Sanofi (Inst); Trillium Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - Serametrix, Inc |
|
|
Employment - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Actym Therapeutics; Adaptive Biotechnologies; Amphivena; Intensity Therapeutics; Torque |
Consulting or Advisory Role - Abbvie; Adaptimmune; Allakos; Almac Diagnostics; Array BioPharma; AstraZeneca/MedImmune; Biodesix; Bristol-Myers Squibb; Celldex; Genentech/Roche; Genmab; Gritstone Bio; Hinge Bio; immunocore; Incyte; Innate Pharma; Inovio Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck Sharp & Dohme; Modulate Pharma; Molecular Partners; Nektar; Newlink Genetics; Novartis; Omniox; Pieris Pharmaceuticals; Pierre Fabre; Seagen; Symphogen; Theravance; Torque |
Other Relationship - AcademicCME; Clinical Care Options; Dava Oncology; Haymarket Media; Imedex; Physicans' Education Resource; Prime Oncology; Research to Practice; TRM Oncology; Vindico |